Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

Inclusion Criteria: * Willing and able to provide written informed consent * Any gender, age ≥ 18 years \< 65 years * Laboratory confirmed documentation of HIV-1 infection. * Continuous therapy with a Department of Health and Human Services (DHHS) recommended/alternative combination ART for least 12 months (at least 3 agents) at study entry with no regimen changes in the preceding 12 weeks * Maintenance of undetectable plasma HIV-1 RNA ( \<40copies/ml) below the limit of quantification for at least 12 months. Episodes of single HIV plasma RNA 50-500 copies/ml will not exclude participation if subsequent HIV plasma RNA is below the limit of assay detection * No plans to modify ART during the study period (approximately 4-5 months) * Participant and partner(s) are willing to use two forms of contraception throughout the study period as well as up to 60 days after the last day of study completion * Ability and availability to participate in the full duration of the study (approximately 4-5 months) and maintain the inclusion/exclusion criteria * No current or prior history of methamphetamine (MA) use disorder by DSM-5 diagnostic criteria. Participants may have a prior history of taking prescription medications containing amphetamines- type stimulants such as Adderall® or Dexedrine® or Ritalin for the treatment of conditions such as attention deficit hyperactivity disorder as long as the participant has not taken these medications in the last 12 months or plans to take these medi…